Antimicrobial resistance in the 21st century: A multifaceted challenge

Protein and Peptide Letters

Volumn 21, Issue 4, 2014, Pages 330-335

  Nolte, O ^a  

^a Laboratory of Dr Brunner   (Germany)

Author keywords

Antimicrobial resistance; Appropriate treatment; Clinical resistance; ESBL; MRSA; NDM 1; Public health

Indexed keywords

BETA LACTAM ANTIBIOTIC; CARBAPENEM; CEFEPIME; CEPHALOSPORIN; CEPHAMYCIN; COLISTIN; MONOBACTAM DERIVATIVE; PENICILLIN DERIVATIVE; TIGECYCLINE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL IMMUNITY; BACTERIAL MUTATION; BACTERIAL STRAIN; BIOLOGICAL TRAIT; COST BENEFIT ANALYSIS; COST OF ILLNESS; DRUG EFFECT; DRUG TREATMENT FAILURE; DRUG USE; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ENTEROBACTERIACEAE; HISTORY; HUMAN; KLEBSIELLA PNEUMONIAE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NEISSERIA GONORRHOEAE; NONHUMAN; PUBLIC HEALTH PROBLEM; STREPTOCOCCUS PYOGENES; VANCOMYCIN RESISTANT ENTEROCOCCUS;

ANIMALS; ANTI-INFECTIVE AGENTS; BACTERIA; BACTERIAL INFECTIONS; CLIMATE CHANGE; DRUG RESISTANCE, BACTERIAL; HISTORY, 21ST CENTURY; HUMANS; PUBLIC HEALTH;

EID: 84896333146     PISSN: 09298665     EISSN: None     Source Type: Journal    
DOI: 10.2174/09298665113206660106     Document Type: Article

References (29)

1. Sheldon, T. Dutch microbiologists are disciplined for delays during pneumonia outbreak. Brit. Med. J., 2012, 344, e755.
2. Appelbaum, P.C. 2012 and beyond: potential for the start of a second pre-antibiotic era? J. Antimicrob. Chemother., 2012, 67, 2062-2068.
3. D'Costa, V.M.; King, C.E.; Kalan, L.; Morar, M.; Sung, W.W.L.; Schwarz, C.; Froese, D.; Zazula, G.; Calmels, F.; Debruyne, R.; Golding, G.B.; Poinar, H.N.; Wright, G. Antibiotic resistance is ancient. Nature, 2011, 477, 457-461.
4. Rammelkamp, C.H.; Maxon, T. Resistance of Staphylococcus aureus to the Action of Penicillin. Exp. Biol. Med., 1942, 51, 386-389.
5. DeFlaun, M.F.; Levy, S.B. In: Gene transfer in the environment. Stuart B Levy, Robert V Miller, Ed. McGraw-Hill New York, 1991, pp. 1-32.
6. Tenover, F.C. Development and Spread of Bacterial Resistance to Antimicrobial Agents: An Overview. Clin. Infect. Dis., 2001, 33(Suppl 3), S108-15.
7. Johnson, A.P.; Woodford, N. Global spread of antibiotic resistance: the example of New Delhi metallo-ß-lactamase (NDM)-mediated carbapenem resistance. J. Med. Microbiol., 2013, 62, 499-513.
8. Wright, A.E. On therapeutic inoculations of bacterial vaccines, and their practical exploitation in the treatment of disease. Brit. Med. J., 1903, 1(2210), 1069-74.
9. Nolte, O. Autogenous vaccination for the treatment of therapyresistant bacterial infections. Relevance as alternative treatment option in an era of increasing antimicrobial resistance. [Zur Diskussion: Die autogene Vakzination als nicht-antimikrobielles Verfahren bei Therapie-resistenten bakteriellen Infektionen - Bedeutung als alternative Behandlungsoption in Zeiten zunehmender antimikrobieller Resistenzproblematik] Chemother. J., 2009, 18, 18-23.
10. Tenover, F.C. Mechanisms of antimicrobial resistance in bacteria. Am. J. Med., 2006, 119, S3-S10.
11. Adler, A.; Gniadkowski, M.; Baraniak, A.; Izdebski, R.; Fiett, J.; Hryniewicz, W.; Malhotra-Kumar, S.; Goossens, H.; Lammens, C.; Lerman, Y.; Kazma, M.; Kotlovsky, T.; Carmeli, Y. and the MOSAR WP5 and WP2 study groups. Transmission dynamics of ESBL-producing Escherichia coli clones in rehabilitation wards at a tertiary care centre. Clin. Microbiol. Infect., 2012, 18, E497-E505
12. Høiby, N.; Bjarnsholt, T.; Givskov, M.; Molin, S.; Ciofu, O. Antibiotic resistance of bacterial biofilms. Int. J. Antimicrob. Agents, 2010, 35, 322-332.
13. Livermore D.M.; Andrews, J.M.; Hawkey, P.M.; Ho, P.-L.; Keness, Y.; Doi, Y.; Paterson, D.; Woodford, N. Are susceptibility tests enough, or should laboratories still seek ESBLs. and carbapenemases directly? J. Antimicrob. Chemother., 2012, 67, 1569-77.
14. The European Committee on Antimicrobial Susceptibility Testing - EUCAST. http://www.eucast.org/ (Accessed May 8, 2013).
15. Clinical and Laboratory Standards Institute. http://www.clsi.org/ (Accessed May 8, 2013).
16. British Society for Antimicrobial Chemotherapy. http://bsac.org.uk/ (Accessed May 8, 2013).
17. Marchese, A.; Esposito, S.; Barbieri, R.; Bassetti, M.; Debbia, E. Does the adoption of EUCAST susceptibility breakpoints affect the selection of antimicrobials to treat acute community-acquired respiratory tract infections? BMC Infect. Dis., 2012, 12, 181.
18. ECDC EARS-Net Database. http://ecdc.europa.eu/en/activities/ surveillance/EARS-Net/database/Pages/database.aspx (Accessed May 8, 2013).
19. Ndowa, F.; Lusti-Narasimhan, M. The threat of untreatable gonorrhoea: implications and consequences for reproductive and sexual morbidity. Reprod. Health Matters., 2012, 20, 76-82.
20. Unemo, M.; Nicholas, R.A. Emergence of multidrug-resistant, extensively drug-resistant and untreatable gonorrhea. Future Microbiol., 2012, 7, 1401-1422.
21. Kumar, A.; Roberts, D.; Wood, K.E.; Light, B.; Parrillo, J.E.; Sharma, S.; Suppes, R.; Feinstein, D.; Zanotti, S.; Taiberg, L.; Gurka, D.; Kumar, A.; Cheang, M. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit. Care Med., 2006, 34, 1589-1595.
22. Rasheed, J.K.; Jay, C.; Metchock, B.; Berkowitz, F.; Weigel, L.; Crellin, J.; Steward, C.; Hill, B.; Medeiros, A.A.; Tenover, F.C. Evolution of extended-spectrum ß-lactam resistance (SHV-8) in a strain of Escherichia coli during multiple episodes of bacteremia. Antimicrob. Agents Chemother., 1997, 41, 647-653.
23. Meyer, K.S.; Urban, C.; Eagan, J.A.; Berger, B.J.; Rahal, J.J. Nosocomial outbreak of Klebsiella infection resistant to lategeneration cephalosporins. Ann. Intern. Med., 1993, 119, 353-358.
24. Otto, M. MRSA virulence and spread. Cell. Microbiol., 2012, 14, 1513-1521.
25. Hersh, A.L.; Chambers, H.F.; Maselli, J.H.; Gonzales, R. National Trends in Ambulatory Visits and Antibiotic Prescribing for Skin and Soft-Tissue Infections. Arch. Intern. Med., 2008, 168, 1585-1591.
26. Brown, K.A.; Khanafer, N.; Daneman, N.; Fisman, D.N. Antibiotics and the risk of community-associated Clostridium difficile infection (CDI): a meta-analysis. Antimicrob. Agents Chemother., 2013, 57, 2326-32.
27. Stewardson, A.; Fankhauser, C.; Giulia De Angelis, M.D.; Rohner, P. Burden of Bloodstream Infection caused by extended-spectrum ß-lactamase- producing Enterobacteriaceae determined using multi state modeling at a Swiss university hospital and a nationwide predictive model. Infect. Contr. Hosp. Epidemiol., 2013, 34, 133-143.
28. de Kraker, M.E.; Davey, P.G.; Grundmann, H. Mortality and hospital stay associated with resistant Staphylococcus aureus and Escherichia coli bacteremia: estimating the burden of antibiotic resistance in Europe. PLoS Med., 2011, 8, e1001104.
29. Centers for Disease Control and Prevention. World Health Day: Media Fact Sheet, April 7, 2011. http://www.cdc.gov/media/ releases/ 2011/f0407- antimicrobialresistance.pdf.